Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Schwerdtfeger

Nurse Practitioner Mount Pleasant, WI Nurse Practitioner

NPI 1235414665 CMS profile 11191309

6233 Bankers Rd, Suite 3, Mount Pleasant, WI 53403

Open in the dashboard

General payments

$14,673

731 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Schwerdtfeger of Mount Pleasant, WI is reported in the CMS Open Payments database as having received $14,673 across 731 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,349 104
2024 General $3,490 140
2023 General $3,096 158
2022 General $2,705 155
2021 General $3,033 174

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Schwerdtfeger
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kimberly Schwerdtfeger were reported at $2,349. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kimberly Schwerdtfeger Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,033 $135 $40–$426 $132
2022 $2,705 $152 $48–$470 $149
2023 $3,096 $166 $54–$529 $160
2024 $3,490 $173 $55–$556 $164
2025 $2,349 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,141 122 payments
  2. Regeneron Healthcare Solutions, Inc. $1,915 75 payments
  3. Lilly USA, LLC $1,441 82 payments
  4. Sun Pharmaceutical Industries Inc. $1,178 50 payments
  5. Amgen Inc. $1,155 52 payments
  6. Janssen Biotech, Inc. $1,081 35 payments
  7. Genzyme Corporation $993 41 payments
  8. LEO Pharma Inc. $786 79 payments
  9. Novartis Pharmaceuticals Corporation $572 28 payments
  10. E.R. Squibb & Sons, L.L.C. $537 28 payments
  11. Other $2,873 139 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,781 719 payments
  2. Education $891 12 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,405 52 payments
  2. DUPIXENT Inflammation And Immunology $1,267 53 payments
  3. TALTZ $1,265 75 payments
  4. Otezla $1,155 52 payments
  5. SKYRIZI $1,053 57 payments
  6. TREMFYA $749 19 payments
  7. OLUMIANT $588 26 payments
  8. RINVOQ $576 29 payments
  9. ILUMYA $562 23 payments
  10. ADBRY $530 43 payments
  11. Other $8,023 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

616

Median for Nurse Practitioner: 389

Drug cost

$374,964

Median for Nurse Practitioner: $21,885

Branded share of claims

7.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 11 $251,013
Humira(Cf) Pen Adalimumab Brand 13 $103,957
Clobetasol Propionate Generic 166 $6,785
Fluorouracil Generic 43 $3,095
Desonide Generic 62 $2,742
Clindamycin Phosphate Generic 31 $1,865
Ketoconazole Generic 106 $1,758
Triamcinolone Acetonide Generic 68 $1,113
Metronidazole Generic 17 $1,013
Doxycycline Hyclate Generic 37 $763

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$152,456

Of which drugs: $14,010

Medicare patients

502

Average age 75

Services billed

3,319

329 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 46%
Diabetes 22%
Ischemic heart disease 20%
Chronic kidney disease 19%
Osteoporosis 18%
Cancer 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 25 45 $13,910
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 157 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$786 — —
SKYRIZI
$323 11 —
Bimzelx
$286 — —
TREMFYA
$273 — —
Zoryve
$268 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

731 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record